Kos Biotechnology Partners is an early-stage venture capital firm deploying capital across biotechnology, therapeutics, genomics, drug discovery, and life sciences sectors. They invest in scientist-founders and biotech entrepreneurs building category-defining therapeutic platforms and drug development companies with operator-investor support. The firm differentiates itself through its Cambridge positioning at the heart of the US biotech ecosystem, dedicated focus on biotechnology and therapeutic platforms, operator-investor expertise from prior biotech executive backgrounds, and concentrated conviction-based investing approach at seed and Series A stages.